Onderneming Satsuma Pharmaceuticals, Inc.
Aandelen
STSA
US80405P1075
Biotechnologie & Medisch Onderzoek
Vakgebied
Aantal werknemers: 25
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 08-06-23 |
Mic Iwashima
COO | Chief Operating Officer | 46 | 01-01-17 |
Chief Tech/Sci/R&D Officer | 63 | 01-07-17 | |
Shannon Strom
LAW | General Counsel | 48 | 01-05-18 |
Corporate Officer/Principal | - | 05-03-20 | |
Robert Schultz
PRN | Corporate Officer/Principal | 60 | 01-07-17 |
Shinji Nitanda
SEC | Corporate Secretary | 55 | 08-06-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 08-06-23 |
Director/Board Member | 64 | 08-06-23 | |
Ken Takanashi
BRD | Director/Board Member | 59 | 01-06-16 |
Shunji Haruta
BRD | Director/Board Member | - | 08-06-23 |
Akihisa Mori
BRD | Director/Board Member | - | 08-06-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 33 152 498 | 27 782 705 ( 83,80 %) | 0 | 83,80 % |
Bedrijfsgegevens
Satsuma Pharmaceuticals, Inc.
4819 Emperor Boulevard Suite 340
27703, Durham
+650 410 3200
http://www.satsumarx.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |